* If you want to update the article please login/register
Mesothelioma is a rare, aggressive cancer caused by asbestos fibers. Mesothelioma patients who receive trimodal therapy live longer than those who receive two or fewer treatment options. This report looks at the 2016-2019 Medicare claims data to determine the prevalence of malignant mesothelioma and outline therapy patterns among continually registered fee-for-service beneficiaries. The annual prevalence of 100 000 beneficiaries varies from 8. 8 in 2016 to 31. 3 in 2019; the annual rate for 100 000 beneficiaries increased from 8. 8 in 2016 to 32 percent in 2017 — from 8. 8 in 2016 to 31. 3 in 2019. According to available therapy report data, 7. 6%-11. 3% received chemotherapy alone, 1. 3%-1. 5% received radiation alone, and 14. 3%-27. 0% underwent surgery only, with 4. 6 percent receiving all three therapy strategies. Medicare findings expand on findings from cancer registry studies to improve our knowledge of the mesothelioma incidence and therapy patterns.
Source link: https://europepmc.org/article/MED/36635096
Background The treatment of recurrent malignant pleural mesothelioma remains difficult. After primary curative-intent surgery, a new MPM's efficacy, tolerability, and safety of nivolumab with ipilimumab therapy for recurrent MPM were investigated by our review. Both administered intravenously, Methods Treatment included 360 mg nivolumab every three weeks and 1 mg/kg of ipilimumab every six weeks. Tumor response in Solid Tumors was assessed using the updated Response Evaluation Criteria. After primary curative-intent surgery, forty-one patients were given nivolumab for recurrent MPM after primary curative-intent surgery. In addition, 47 AEs were reported in 29 patients, including grade 3-4 AEs in 14 patients. In 2 patients and grade 4 neutropenia was observed in 1, and grade 4 neutropenia was present in 1. Conclusions The Nivolumab treatment of patients with recurrent MPM after primary surgical surgery may be clinically beneficial, but serious AEs may be present.
Source link: https://europepmc.org/article/MED/36609928
Pleural mesothelioma is a rare disease with a poor prognosis and no therapeutic options. The median overall survival for a pleural mesothelioma patient was up to two years until recently, with few rare cases of patients surviving longer than others. The patient underwent several systemic therapies, including three distinct chemotherapy lines and two immunotherapy regimens using immune checkpoint inhibitors.
Source link: https://europepmc.org/article/MED/36599413
History & Migrant peritoneal mesothelioma is a rare disease with a notoriously poor prognosis. Methods The SEER-18 registry database was analyzed, according to the researchers. To determine survival trends, multivariable cox proportional hazards models were used. Epithelioid histology increased by 24%, though undefined histology reduced dramatically. The number of patients treated with cancer-directed surgery increased from 27 percent to 43 percent. 16. 6 months for epithelioid histology but 2. 0 months for sarcomatoid histology were standardized among the median age groups. Conclusions Although overall incidence of MPM remained stable, epithelioid histology increased. MPM survival has increased as a result of an increase in cancer-directed surgery.
Source link: https://europepmc.org/article/MED/36612225
Tumor-Treating Fields therapy is a new therapeutic technique in clinical use for patients with advanced cancers, based on the principle of using low-intensity alternating electric fields to disrupt microtubules in cancer cells undergoing mitosis. In this research, we investigated the effects of TTFields on TNTs in malignant pleural mesothelioma in vitro and in vivo's spatial transcriptomic landscape. TNT formation in a biphasic MPM cell line was greatly reduced by using TTFields at 1. 0 V/cm, but not in sarcomatoid MPM. We investigated how TTFields may influence gene expression and overall tumor formation in an in-vivo animal model of MPM, and found rise in immuno-oncological biomarkers with simultaneous downregulation of cell proliferation, invasion, and other important regulators of oncogenic growth. Several molecular classes and pathways correlate with markers that we and others have discovered to be differentially expressed in cancer cell TNTs, including MPM specifically. We review novel cellular and molecular consequences of TTFields in connection with tumor communication networks enabled by TNTs and other molecular pathways in this study. These findings place TNTs as potential therapeutic targets for TTFields-directed cancer treatment strategies; as well as identify the ability of TTFields to potentially remodel the tumor microenvironment, improving response to immunotherapeutic drugs.
Source link: https://europepmc.org/article/PPR/PPR590566
Background The role of cancer-directed surgery in the treatment of stage I-IIIA malignant pleural mesothelioma by histologic subtypes remains unclear. How is the histological subtype, clinical stage, and use of cancer-directed surgery with MPM in MPM has been associated with overall survival? The National Cancer Database's research and methods Overall survival of patients with stage I-IIIA epithelioid, sarcomatoid, and biphasic MPM in the National Cancer Database from 2004-2017 who underwent cancer-directed surgery or chemotherapy with or without radiation was assessed using KaplanMeier analysis, multivariable Cox proportional hazards analysis, and propensity score-matched analysis. In 71% of patients, epithelioid in 71%, sarcomatoid in 12 percent, and biphasic in 17% of patients. Interpretation of the Patient In this national review, cancer-directed surgery was found to be responsible for improved longevity for stage I-IIIA epithelioid MPM but not for biphasic or sarcomatoid MPM.
Source link: https://europepmc.org/article/MED/36574925
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions